Recently, the category 1 innovative product Deucravacitinib Tablets (trade name: Sotyktu) of Bristol Myers Squibb is approve for marketing by China NMPA. This drug is indicated for adults with moderate-to-severe plaque psoriasis through systematic treatment or phototherapy.

　　Deucravacitinib is a tyrosine kinase 2 (TYK2) inhibitor. The marketing of this drug will provide new treatment options for patients with moderate-to-severe plaque psoriasis.